Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14457987 | 1.00 | RAPGEF4 (0.38) | RAPGEF4ALDH1A1CYP3A4ADRA2AKDM4E | |
| SCHEMBL13987030 | 1.00 | RAPGEF4 (0.38) | RAPGEF4ALDH1A1CYP3A4ADRA2AKDM4E | |
| SCHEMBL4854848 | 1.00 | RAPGEF4 (0.38) | RAPGEF4ALDH1A1CYP3A4ADRA2AKDM4E | |
| SCHEMBL29395663 | 0.81 | RAPGEF4 (0.36) | RAPGEF4ALDH1A1CYP3A4ADRA2AKDM4E | |
| SCHEMBL17669763 | 0.79 | RAPGEF4 (0.35) | RAPGEF4ALDH1A1CYP3A4ADRA2AKDM4E | |
| SCHEMBL21860490 | 0.77 | — | — | |
| SCHEMBL23644548 | 0.77 | KMT2A (0.33) | RAPGEF4ALDH1A1GAAKMT2A | |
| SCHEMBL23644547 | 0.77 | KMT2A (0.33) | RAPGEF4ALDH1A1GAAKMT2A | |
| SCHEMBL11856863 | 0.75 | RAPGEF4 (0.37) | RAPGEF4ALDH1A1CYP3A4ADRA2A | |
| SCHEMBL11281680 | 0.75 | CYP3A4 (0.57) | RAPGEF4ALDH1A1CYP3A4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250244419-A1 | INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250242340-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4505201-A1 | INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4504404-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2023196602-A1 | INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3394121-B1 | PROCESS FOR THE PREPARATION OF (CO) POLYMERS OF CONJUGATED DIENES IN THE PRESENCE OF A CATALYTIC SYSTEM COMPRISING A VANADIUM BIS-IMINE COMPLEX | VERSALIS SPA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-20220152208-A1 | NON-IONIC BLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM | Altus Formulation Inc. (CA) | 2022-05-19 | — | — | US | disclosed |
| US-11299505-B2 | Bis-imine titanium complex, catalytic system comprising said bis-imine titanium complex and process for the (co)polymertzation of conjugated dienes | VERSALIS S.P.A. (IT) | 2022-04-12 | — | — | US | disclosed |
| US-20140228206-A1 | BIS-IMINE COMPLEX OF LANTHANIDES, CATALYTIC SYSTEM COMPRISING SAID BIS-IMINE COMPLEX AND PROCESS FOR THE (CO)POLYMERIZATION OF CONJUGATED DIENES | VERSALIS S.P.A. (IT) | 2014-08-14 | — | — | US | disclosed |
| US-20140228206-A1 | BIS-IMINE COMPLEX OF LANTHANIDES, CATALYTIC SYSTEM COMPRISING SAID BIS-IMINE COMPLEX AND PROCESS FOR THE (CO)POLYMERIZATION OF CONJUGATED DIENES | VERSALIS S.P.A. (IT) | 2014-08-14 | — | — | US | disclosed |
| US-20130261312-A1 | SUPPORTED OLEFIN METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261312-A1 | SUPPORTED OLEFIN METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013037910-A1 | BIS-IMINE COMPLEX OF LANTHANIDES, CATALYTIC SYSTEM COMPRISING SAID BIS-IMINE COMPLEX AND PROCESS FOR THE (CO)POLYMERIZATION OF CONJUGATED DIENES | VERSALIS S.P.A. (IT) | 2013-03-21 | — | — | WO | disclosed |
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2011069134-A2 | SUPPORTED OLEFIN METATHESIS CATALYSTS | MATERIA, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-7470750-B2 | Method for the degradation of nitrile rubber by metathesis in the presence of ruthenium- or osmium-based catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070049700-A1 | Method for the degradation of nitrile rubber by metathesis in the presence of ruthenium- or osmium-based catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250244419-A1 | INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES | MPI, HAMP, HIF1A | RAPGEF4 1420/4885ALDH1A1 3474/4885CYP3A4 1446/4885 |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | XDH, OXA1L, AOX1 | RAPGEF4 3992/4885ALDH1A1 421/4885CYP3A4 128/4885 |
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | RAPGEF4 4067/4885ALDH1A1 4484/4885CYP3A4 4655/4885 |
| US-20220152208-A1 | NON-IONIC BLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM | F11, F13B, F10 | RAPGEF4 1288/4885ALDH1A1 1912/4885CYP3A4 210/4885 |
| US-20250242340-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | RAPGEF4 4067/4885ALDH1A1 4484/4885CYP3A4 4655/4885 |
| US-11299505-B2 | Bis-imine titanium complex, catalytic system comprising said bis-imine titanium complex and process for the (co)polymertzation of conjugated dienes | AOC2, AOC1, AOC3 | RAPGEF4 2575/4885ALDH1A1 1005/4885CYP3A4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.